

UBS (Lux) Equity Fund - Asian Consumption (USD)

Important information:

- The Fund primarily invests in ordinary and preferred shares, including ADRs, warrants on transferable securities and equity rights which can be converted into ordinary shares, and other equity securities of companies that are engaged in the business activities of providing goods and services to Asian consumers.
- The Fund invests in certain Asian markets that are classified as 'emerging markets'. Investment in emerging markets suffer from certain risks such as increased risk of expropriation, nationalization and social, political and economic insecurity; acquisition of counterfeit securities by the Fund; low liquidity and high price (and performance) volatility; substantial currency fluctuations; settlement and custody risks; restrictions on the buying of securities by foreign investors; accounting, auditing and reporting standards, methods, practices and disclosures required by companies in emerging markets being different from those in developed markets.
- The Fund may invest up to 100% of its assets in financial derivative instruments to gain or reduce exposure to markets and currencies as well as to manage risk. The use of derivatives may involve additional risk, e.g. general market risk, management risk, credit, liquidity risk. Under extreme market conditions and circumstances, the use of derivative financial instruments may potentially result in total loss.
- Investors should not invest in the Fund solely based on this document and should read the relevant offering document.




Morningstar rating TM
as at 31-01-2021



Investment objective & strategy

- Actively managed equity portfolio that invests throughout Asia in companies in the consumer staples, consumer discretionary and healthcare sectors.
- Efficient means of exploiting the potential of companies who offer goods and services to consumers in Asia. The focus lies on those companies who stand to benefit more from Asian consumer growth.
- Specialised sector analysts seek out the most attractive stocks mainly in the consumer goods and health care sector.

Performance since 2009 (share class P-acc; basis USD, net of fees) ¹



- Indexed performance (left-hand scale)
- Performance per year in % (right-hand scale)
- MSCI AC Asia ex Japan Consumer & Healthcare Sectors 10/40 Index

Name of fund	UBS (Lux) Equity Fund – Asian Consumption
Currency of fund	USD
Currency of share class	USD
Fund type	Open-end
Accounting year ends	30 November
Issue/redemption	Daily
Total fund assets (USD m)	202.33
Front End Load	P-acc: up to 5% of subscription amount
Ref Index	MSCI AC Asia ex Japan Consumer & Healthcare Sectors 10/40 Index

in %	Year-to-date	1 year	3 years	5 years	Since Repositioning [*]
Fund (USD) P-acc	2.95	40.08	35.67	118.89	203.29
Ref Index ²	3.89	58.21	34.31	101.18	396.56
in %	2016	2017	2018	2019	2020
Fund (USD) P-acc	-1.78	49.44	-15.80	24.02	31.43
Ref Index ²	-	38.05	-23.29	20.91	45.97

¹ Fund performance is calculated on NAV to NAV basis in denominated currency of the respective share class with dividends re-invested. These figures refer to the past. Past performance is not a reliable indicator of future results. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units. Source for all data and charts (if not indicated otherwise): UBS Asset Management

² Ref Index in currency of share class (without costs)

* The Fund repositioned to current strategy on 21 July 2009.

The value of the funds and income from them can go up as well as down and consequently you may not get back the amount originally invested. The document has not been reviewed by the Securities and Futures Commission in Hong Kong. The investment returns of some of our range of funds are denominated in currency other than USD/HKD. US/HK Dollar-based investors are therefore exposed to fluctuations in the US/HK dollar/ foreign currency exchange rate. Investment involves risks, and past performance figures shown are not indicative of future performance. Investors please refer to the offering document for further details including the risk factors. Units of UBS funds mentioned in this publication may not be offered, sold or delivered in the USA. The document is issued by UBS Asset Management (Hong Kong) Limited. © UBS 2021. All rights reserved

Share class details

	P-acc
Net asset value (USD, 29.01.2021)	202.87
Last 12 Months(USD) – high	214.46
– low	115.46
management fee % p.a.	1.63
Securities number	1 041 161
ISIN	LU0106959298
Bloomberg	UBSATEC LX
Launch Date	10.03.2000 ²
Distribution	Reinvestment

²Following the realignment of UBS investment fund range, asset allocation for this fund was adjust with effect from 21.07.2009. All performance details thus refer to the date of the repositioning

Fund statistics

	3 years	5 years
Beta	0.89	0.90
Volatility ¹		
– Fund	19.07%	16.61%
– Ref Index	20.04%	16.89%
Sharpe ratio	0.48	0.94
Risk free rate	1.61%	1.33%

¹ Annualised standard deviation

Market exposure (%)

	Fund
China	+60.9
India	+19.9
Hong Kong	+6.5
Republic of Korea	+4.5
Taiwan	+2.7
Philippines	+1.9
Thailand	+1.9
Singapore	+1.2
Macau	+0.6
Others	0.0

Sector exposure (%)

	Fund
Consumer Discretionary	38.1
Consumer Staples	30.2
Health Care	4.8
Others	27.0